StockData

Traws Pharma vs Upstream Bio

TRAW and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

trawTraws Pharma$0.25−88.3% in 1 yearupbUpstream Bio$2.78−88.3% in 1 year

How TRAW and UPB compare

Upstream Bio is the larger company, worth 39 times as much as Traws Pharma ($152M against $3.9M).

Upstream Bio scores higher on the StockData Score (8 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTRAWUPB
Size and price
Market cap$3.9M$152M
Share price$0.251$2.78
Change, 1 year−88.3%−88.3%
Change, 5 years−99.7%–
Beta (5Y)1.191.28
Employees775
StockData Score
Total score58 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score46 (better)
Dividend score00
Valuation
P/S–53.1×
P/B–0.7×
Growth
Revenue growth (TTM)–2.5%
Revenue growth, 5Y average64.6%–
Profitability
Operating margin–−6116%
Net margin–−5712%
Return on equity–−53.5%
Return on invested capital–−846%
Financial health
Debt / equity–0.00
Current ratio0.9320.45 (better)
Altman Z-score−85.393.80 (better)
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield−109%–
Shareholder yield−109%0.00% (better)
Ownership
Held by institutions40.1%92.3%
Held by insiders35.7%8.6%
Insider net buying, 12 months$998K (better)−$105K
Short interest, % of float6.9%7.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.